Goldman Sachs’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Goldman Sachs’s Portfolio SLXNW Stock Details SLXNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.51K	Buy	123,494 +2,257	+2%	+$71	﹤0.01%	6417
2025 Q4	$3.15K	Buy	121,237 +4,598	+4%	+$163	﹤0.01%	6392
2025 Q3	$4.11K	Buy	116,639 +3,071	+3%	+$108	﹤0.01%	6281
2025 Q2	$4.64K	Buy	113,568 +3,476	+3%	+$184	﹤0.01%	6021
2025 Q1	$8.42K	Buy	110,092 +2,617	+2%	+$159	﹤0.01%	5976
2024 Q4	$3.64K	Buy	107,475 +14,188	+15%	+$570	﹤0.01%	5963
2024 Q3	$2.94K	Buy	+93,287	New	+$5.4K	﹤0.01%	5753

Other funds holding SLXNW

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.39% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Goldman Sachs's SLXNW Position: Q1 2026 in Review

Goldman Sachs increased its Silexion Therapeutics Warrant (SLXNW) stake by 1.9% in Q1 2026, buying an estimated $71 and bringing the position to 123,494 shares worth $2.51K. The position accounts for ﹤0.01% of the portfolio, ranked #6417.

Goldman Sachs first reported a position in SLXNW in Q3 2024 and has held it in 7 quarters since. The position peaked at $8.42K in Q1 2025. 19 funds tracked by Wall St. Rank hold SLXNW as of Q1 2026.

Goldman Sachs held 123,494 shares of Silexion Therapeutics Warrant worth $2.51K as of Q1 2026.
Goldman Sachs bought 2,257 Silexion Therapeutics Warrant shares in Q1 2026, an estimated $71.
Silexion Therapeutics Warrant made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6417 holding.
Goldman Sachs first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 7 quarters since.
Goldman Sachs's Silexion Therapeutics Warrant position peaked at $8.42K in Q1 2025.
19 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.